UBS Maintains Neutral on CYTK, Cytokinetics, Incorporated March 2026
On March 06, 2026 UBS maintained a Neutral rating on Cytokinetics, Incorporated and raised the price target to $69. The CYTK analyst rating news came at 07:51 AM and cited an improved outlook for the company’s nHCM program. We see the update as a refinement of risk versus reward, not a directional buy signal.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
